| Mansoor Ahmad, MD | |
|
1313 S St, Bridgeport, NE 69336-2563 | |
| (308) 262-1616 | |
| Not Available |
| Full Name | Mansoor Ahmad |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Experience | 11 Years |
| Location | 1313 S St, Bridgeport, Nebraska |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1639583321 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Morrill County Community Hospital | Bridgeport, NE | Hospital |
| Twin County Regional Hospital | Galax, VA | Hospital |
| St Mary Corwin Med Ctr, Centura Health | Pueblo, CO | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Emergency Coverage Corp | 3072412592 | 364 |
| Morrill County Community Hospital | 7719930437 | 19 |
| Southeastern Intensivist Services Pc | 9335152107 | 218 |
News Archive
Screening for autism at three years of age only identifies those with significant developmental delay, and not those with less severe autism. Early screening may therefore not be as beneficial as previously thought, according to data from the Norwegian Mother, Father and Child Cohort Study.
NeuroSigma, Inc., a Los Angeles-based medical device company, today announced the formation of a majority owned subsidiary, NSVascular, Inc. and the signing of an exclusive license with the University of California, Los Angeles (UCLA) covering its medical applications of Thin-Film Nitinol (TFN) technology. Nitinol is a superelastic nickel and titanium alloy with unique properties that allow deformation and subsequent full recovery of the original shape upon exposure to body heat.
The Springer journal Analytical and Bioanalytical Chemistry (ABC) has chosen Jean-Philippe Frimat (29) as the recipient of its Best Paper Award 2009. Frimat is the lead author of a paper in ABC on plasma stencilling methods for cell patterning.
Cempra Inc., a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases,today announced that data will be presented at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), in London, March 31 to April 3,demonstrating CEM-101's (solithromycin's) efficacy to be comparable to levofloxacin in a Phase 2 trial of patients with community-acquired bacterial infections.
› Verified 1 days ago
| Entity Name | Emergency Coverage Corp |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1427005008 PECOS PAC ID: 3072412592 Enrollment ID: O20050418000414 |
News Archive
Screening for autism at three years of age only identifies those with significant developmental delay, and not those with less severe autism. Early screening may therefore not be as beneficial as previously thought, according to data from the Norwegian Mother, Father and Child Cohort Study.
NeuroSigma, Inc., a Los Angeles-based medical device company, today announced the formation of a majority owned subsidiary, NSVascular, Inc. and the signing of an exclusive license with the University of California, Los Angeles (UCLA) covering its medical applications of Thin-Film Nitinol (TFN) technology. Nitinol is a superelastic nickel and titanium alloy with unique properties that allow deformation and subsequent full recovery of the original shape upon exposure to body heat.
The Springer journal Analytical and Bioanalytical Chemistry (ABC) has chosen Jean-Philippe Frimat (29) as the recipient of its Best Paper Award 2009. Frimat is the lead author of a paper in ABC on plasma stencilling methods for cell patterning.
Cempra Inc., a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases,today announced that data will be presented at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), in London, March 31 to April 3,demonstrating CEM-101's (solithromycin's) efficacy to be comparable to levofloxacin in a Phase 2 trial of patients with community-acquired bacterial infections.
› Verified 1 days ago
| Entity Name | Southeastern Intensivist Services Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1912942665 PECOS PAC ID: 9335152107 Enrollment ID: O20190131001122 |
News Archive
Screening for autism at three years of age only identifies those with significant developmental delay, and not those with less severe autism. Early screening may therefore not be as beneficial as previously thought, according to data from the Norwegian Mother, Father and Child Cohort Study.
NeuroSigma, Inc., a Los Angeles-based medical device company, today announced the formation of a majority owned subsidiary, NSVascular, Inc. and the signing of an exclusive license with the University of California, Los Angeles (UCLA) covering its medical applications of Thin-Film Nitinol (TFN) technology. Nitinol is a superelastic nickel and titanium alloy with unique properties that allow deformation and subsequent full recovery of the original shape upon exposure to body heat.
The Springer journal Analytical and Bioanalytical Chemistry (ABC) has chosen Jean-Philippe Frimat (29) as the recipient of its Best Paper Award 2009. Frimat is the lead author of a paper in ABC on plasma stencilling methods for cell patterning.
Cempra Inc., a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases,today announced that data will be presented at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), in London, March 31 to April 3,demonstrating CEM-101's (solithromycin's) efficacy to be comparable to levofloxacin in a Phase 2 trial of patients with community-acquired bacterial infections.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mansoor Ahmad, MD 1313 S St, Bridgeport, NE 69336-2563 Ph: (308) 262-1616 | Mansoor Ahmad, MD 1313 S St, Bridgeport, NE 69336-2563 Ph: (308) 262-1616 |
News Archive
Screening for autism at three years of age only identifies those with significant developmental delay, and not those with less severe autism. Early screening may therefore not be as beneficial as previously thought, according to data from the Norwegian Mother, Father and Child Cohort Study.
NeuroSigma, Inc., a Los Angeles-based medical device company, today announced the formation of a majority owned subsidiary, NSVascular, Inc. and the signing of an exclusive license with the University of California, Los Angeles (UCLA) covering its medical applications of Thin-Film Nitinol (TFN) technology. Nitinol is a superelastic nickel and titanium alloy with unique properties that allow deformation and subsequent full recovery of the original shape upon exposure to body heat.
The Springer journal Analytical and Bioanalytical Chemistry (ABC) has chosen Jean-Philippe Frimat (29) as the recipient of its Best Paper Award 2009. Frimat is the lead author of a paper in ABC on plasma stencilling methods for cell patterning.
Cempra Inc., a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases,today announced that data will be presented at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), in London, March 31 to April 3,demonstrating CEM-101's (solithromycin's) efficacy to be comparable to levofloxacin in a Phase 2 trial of patients with community-acquired bacterial infections.
› Verified 1 days ago